Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. The company recently received the “Drug Registration Certificate” for ibutinib capsules issued by the State Drug Administration. Ibutinib is a small-molecule BTK (Bruton tyrosine kinase) inhibitor that forms covalent bonds with cysteine residues at BTK active sites, thereby inhibiting BTK's enzymatic activity. BTK is a signaling molecule for the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK activates pathways necessary for B-cell migration, chemotaxis, and adhesion through B-cell surface receptor signaling.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.